Connection
Joseph Saseen to Clinical Trials as Topic
This is a "connection" page, showing publications Joseph Saseen has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.289 |
|
|
|
-
Marrs JC, Saseen JJ. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Pharmacotherapy. 2010 Aug; 30(8):823-9.
Score: 0.059
-
Vande Griend JP, Saseen JJ. Combination antiplatelet agents for secondary prevention of ischemic stroke. Pharmacotherapy. 2008 Oct; 28(10):1233-42.
Score: 0.052
-
Noviasky J, Lo V, Luft DD, Saseen J. Clinical inquiries. Which medications can be split without compromising efficacy and safety? J Fam Pract. 2006 Aug; 55(8):707-8.
Score: 0.045
-
Saseen JJ. ASHP therapeutic position statement on the daily use of aspirin for preventing cardiovascular events. Am J Health Syst Pharm. 2005 Jul 01; 62(13):1398-405.
Score: 0.042
-
Saseen JJ, MacLaughlin EJ, Westfall JM. Treatment of uncomplicated hypertension: are ACE inhibitors and calcium channel blockers as effective as diuretics and beta-blockers? J Am Board Fam Pract. 2003 Mar-Apr; 16(2):156-64.
Score: 0.035
-
Orringer CE, Jacobson TA, Saseen JJ, Brown AS, Gotto AM, Ross JL, Underberg JA. Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. J Clin Lipidol. 2017 Jul - Aug; 11(4):880-890.
Score: 0.024
-
Saseen JJ, Carter BL. Dual calcium-channel blocker therapy in the treatment of hypertension. Ann Pharmacother. 1996 Jul-Aug; 30(7-8):802-10.
Score: 0.022
-
Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004; 18(13):911-32.
Score: 0.009